In previously presented studies, this design enabled efficient T-cell engagement and antigen-dependent cytotoxicity against CD38-positive myeloma cells, supporting the feasibility of CD3-redirecting strategies targeting plasma cell antigens (Figure 3). The gene discussed is CD38; the disease is plasma cell myeloma.